Graves' Disease Occurring after Surgery of a Multinodular Goiter: A Case Report

Abstract

The transition of toxic or nodular goiter to Graves’ disease is known as a rare side effect of ¹³¹I therapy. Here, we report the case of a 46-year-old German female with posttherapeutical Graves’ disease after surgery of a multinodular goiter. Although the major part of the thyroid was excised the patient suffered from manifest Graves’ disease including typical clinical and laboratory findings. Prior to surgery, no TSH receptor antibodies were found, although low TPO antibody titres could already be detected. It may thus be assumed that the therapeutic manipulation elicited the key change towards a TSH receptor antibody production in a predisposed organ or alternatively deteriorated a mild unapparent pre-existing Graves’ disease. It might be concluded that the possibility of posttherapeutical Graves’ disease should be considered in the presence of TPO antibodies prior to the surgical intervention.

Key words

Graves’ disease - multinodular goiter - surgery - TPO antibodies

References

• 1 Bagnasco M, Bossert I, Pesce G. Stress and autoimmune thyroid diseases.  Neuroimmunomodulation. 2006;  13 309-317
• 2 Canonica GW, Caria M, Bagnasco M, Cosulich ME, Giordano G, Moretta L. Proliferation of T8-positive cytolytic T lymphocytes in response to thyroglobulin in human autoimmune thyroiditis: analysis of cell interactions and culture requirements.  Clin Immunol Immunopathol. 1985;  36 40-48
• 3 Dunkelmann S, Wolf R, Koch A, Kittner C, Groth P, Schuemichen C. Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay.  Eur J Nucl Med Mol Imaging. 2004;  31 1428-1434
• 4 Kay TW, Heyma P, Harrison LC, Martin FI. Graves disease induced by radioactive iodine.  Ann Intern Med. 1987;  107 857-858
• 5 Misaki T, Iwata M, Kasagi K, Iida Y, Akamizu T, Kosugi S, Konishi J. Hyperthyroid Graves’ disease after hemithyroidectomy for papillary carcinoma: report of three cases.  Endocr J. 2000;  47 191-195
• 6 Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.  Thyroid. 1999;  9 477-481
• 7 Schmidt M, Gorbauch E, Dietlein M, Faust M, Stutzer H, Eschner W, Theissen P, Schicha H. Incidence of postradioiodine immunogenic hyperthyroidism/Graves’ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.  Thyroid. 2006;  16 281-288
• 8 Seplowitz AH, Ditkoff BA, Papadopoulos AD, Gerfo PL. Sequential occurrence of toxic nodular goiter followed by Graves’ disease.  Endocr Pract. 1998;  4 150-152
• 9 Takamura Y, Nakano K, Uruno T, Ito Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves’ disease after total or subtotal thyroidectomy.  Endocr J. 2003;  50 595-601
• 10 Leussen JJ Van, Edelbroek MA, Talsma MA, Heide LJ de. Graves’ disease induced by Na(131)I therapy for toxic multinodular goiter.  Neth J Med. 2000;  57 194-197

Correspondence